Nian 2019 11 Yue 8 days, Brilliant biomedicine (Suzhou) Co., Ltd. (hereinafter referred to as "Brilliant medicine") on the Shanghai Stock Exchange Branch board formally listed, the stock short "Brilliant medicine" , stock code 688 166  The current issue price is 12.71 yuan / share , the number of issues is 41 million shares , and the total raised funds is about 520 million yuan . Borui Pharmaceuticals intends to raise funds for the construction of the "Taixing API and Preparation Production Base ( Phase 1 )" , expand the production capacity of related products, promote the industrialization of the company's related scientific and technological innovation achievements, and consolidate the company's technological leadership and sustainable development capabilities . With the resounding gong, Borui Medicine has entered the capital market and opened a new chapter of development.

Zhu Min, Deputy Secretary of the Suzhou Municipal Party Committee of Jiangsu Province, Secretary of the Party Leadership Group of Jiangsu Provincial Drug Administration and Director Wang Yue attended the opening ceremony and congratulated

Promoter shareholders and important guests are listed

Speech by Dr. Jiandong Yuan, Chairman of Borui Medicine, at the Listing Ceremony

About Borui Medicine

Borui Biopharmaceutical (Suzhou) Co., Ltd. was founded by Dr. Yuan Jiandong, a specially invited expert of the National "Thousand Talents Program". It is committed to the research and development and production of high-end generic drugs and original innovative drugs, and strives to become a leading global innovative pharmaceutical company.

R & D-driven anchoring innovative enterprises, strategic layout of intellectual property

R & D-driven, continuous innovation, and improving the soft power of science and technology are the core development strategies of Borui Medicine. R & D investment each year revenue accounts for about 25% ; 200 people R & D team accounting for all employees 40% ; patent 400 multinomial, has authorized 105 items are " national IPR advantageous enterprises " . The entecavir synthetic patent, which won the " China Patent Award " , broke the original monopoly and saved billions of yuan in treatment costs for patients with hepatitis B every year.

Build high-tech barriers, highlighting the core excellent potential

The four technology platforms of self-established fermentation semi-synthesis, multi-chiral drugs, targeted polymer coupling and non-biological macromolecules are leading the world, and have successfully developed high-end imitations such as irizbrin and fondaparinux sodium Pharma has established product lines with global competitive advantages in the fields of anti-tumor, super antibiotics, and intravenous iron supplementation. Two new anti-tumor drugs and one new drug for hepatitis B have been approved for clinical development. Currently, six new drugs for diabetes, non-alcoholic fatty liver and super antibiotics have entered preclinical research.

Building a diversified profit model with support for future performance

Borui Pharmaceuticals actively participates in international competition and penetrates the entire industrial chain from "starting materials → difficult intermediates → characteristic APIs → preparations". The factory's cGMP production system has passed official certifications in China, the United States, Europe, Japan and South Korea. , Products are sold in many countries and regions around the world. Its main products, such as caspofungin, have been commissioned by German companies to produce them. It has already occupied 80% of the market share in Europe , and has been authorized to share the profits of downstream customers.

Be grateful to all sectors of the society and strive to build an industry-leading company

The successful listing shows the industry investors' confidence and recognition of Borui Pharmaceuticals and fully reflects the company's strong development potential. Leveraging the power of the capital market, Borui Pharmaceutical will have stronger development resources and a broader development platform. Relying on a strong product line and continuous innovation capabilities, Borui Pharmaceutical will continue to be based in China, look internationally, and strive to become a domestic pharmaceutical enterprise innovation And international pioneer.

Borui Medicine will take the listing as an opportunity, continue to focus on "continuous innovation, protect the health", and continue to seek breakthroughs, with outstanding operating performance to return to the majority of investors, the community's support and love.

Contact us
Email: ir@bright-gene.com  
Tel : +86 (512) 6262-0988 (switchboard)